Status:
RECRUITING
REgiStry-based Cardiovascular qUality improvEment Research
Lead Sponsor:
Peking University Third Hospital
Collaborating Sponsors:
Peking University
Conditions:
Percutaneous Coronary Intervention
Heart Failure
Eligibility:
All Genders
18+ years
Brief Summary
The goal of this registry-based observational study is to establish a comprehensive management plan, which focus on medical therapy, cardiac rehabilitation and active post-market surveillance of medic...
Detailed Description
This is a long-term registry, which will continuously enroll patients and approximately 2000 subjects will be enrolled during the first phase. Primary analyses may include, but will not be limited to...
Eligibility Criteria
Inclusion
- Patients aged ≥ 18 years with cardiovascular diseases who are hospitalized at the Department of Cardiology of Peking University Third Hospital after April 24th, 2023;
- Patients meet the following disease definitions:
- PCI group: Patients underwent percutaneous coronary intervention (PCI) or coronary angiography;
- HF group: Patients diagnosed with heart failure;
- Cardiometabolic Disease (CMD) group: Patients with cardiovascular disease (primarily including coronary artery disease, peripheral artery disease, and aortic disease) and coexisting metabolic disorder (defined as obesity \[BMI≥28 kg/m\^2\], prediabetes and diabetes, hypertension, hyperlipidemia, thyroid dysfunction, and non-alcoholic fatty liver disease);
- Structural Heart Disease (SHD): Patients with structural heart disease, including
- Congenital heart diseases (such as ventricular septal defect, atrial septal defect, patent ductus arteriosus, tetralogy of Fallot, etc.);
- Heart valve diseases (mitral valve, tricuspid valve, aortic valve, pulmonary valve, etc.);
- Cardiomyopathies (hypertrophic cardiomyopathy, dilated cardiomyopathy, etc.);
- Conditions associated with other diseases or acquired structural abnormalities of the heart (ventricular septal perforation, ventricular aneurysm, iatrogenic atrial septal defect, etc.);
- Conditions resulting from other diseases that cause abnormal heart function, which can be corrected by altering cardiovascular structure (such as left atrial appendage dysfunction caused by atrial fibrillation, abnormal cardiac function caused by heart failure);
- Others: Intracardiac thrombosis, cardiac tumors, pericardial diseases, etc.
Exclusion
- patients with no informed consent form (ICF) or who withdraw ICF；
- patients with cognitive impairment or those unable to complete the questionnaire required in the study;
- patient who is pregnant.
Key Trial Info
Start Date :
April 24 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2026
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT06137885
Start Date
April 24 2023
End Date
May 1 2026
Last Update
November 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University Third Hospital
Beijing, Beijing Municipality, China, 100191